Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

GLP-1 agonists may help reduce acetazolamide dosage in patients with idiopathic intracranial hypertension without changing clinical outcome.

Body mass index (BMI) has long been a common tool for estimating a person's relative weight status based on a simple height to weight ratio. It's easy to calculate, widely accessible and often used ...

The U.S. Food and Drug Administration (FDA) already declared that shortages of popular GLP-1 medications have ended, CNN reported. Those medications include semaglutide (Ozempic and Wegovy) and ...

Regeneron Pharmaceuticals has signed a new licensing agreement with Hansoh Pharmaceuticals Group to develop and sell its weight loss therapy outside of China.

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the ...

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

A federal deadline ending the sale of compounded semaglutide (Ozempic, Wegovy) is now in effect after a similar one for ...

ORLANDO, Florida — Extreme fatigue, bone loss, and abdominal pain are real-world adverse events noted with the use of glucagon-like peptide 1 receptor agonists (GLP-1s) that may not have been ...

“So the question is: Is there going to be increased pressure on the starting doses of tirzepatide and semaglutide?” The restrictions on compounded GLP-1 products come as concerns about ...